Mizuho Securities Reiterates Arcutis Biotherapeutics (ARQT) at Buy with $58 PT, Cites De-Risked Phase 3 Trials and High Likelihood of FDA Approval of roflumilast Cream
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $58.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
